The collaboration leverages Theraclone I-STAR technology, which is used to screen and identify novel human antibodies to pathogenic agents and endogenous therapeutic targets, to discover monoclonal antibodies against up to four undisclosed targets.
Theraclone Sciences chief executive officer Clifford Stocks said the collaboration with Pfizer continues to demonstrate the power of I-STAR technology to identify unique antibodies against novel targets.
Theraclone Sciences chief scientific officer Dr. Kristine Swiderek said,"Pfizer’s selection of a third target increases confidence in our approach to search the human immune repertoire to isolate rare and powerful human antibodies that may be of use in the treatment of multiple diseases," added.
As the first and second target discovery programs are successfully nearing completion, Pfizer gains an exclusive worldwide license to the therapeutic antibodies discovered while Theraclone will earn an undisclosed funding as a result of the third target selection.